Biovica International reported a 56% increase in net sales for the first quarter of fiscal 2026/27, driven by strong momentum in its Pharma Services business, while also announcing a fully guaranteed rights issue of SEK 29.2 million to fund its next phase of growth. Net sales reached KSEK 4,043, up from KSEK 2,596 in the same period last year, with local currency growth of 57%. Operating loss widened to KSEK -20,334, including KSEK 2,200 in restructuring costs, as the company streamlined operations and terminated its agreement with Tempus AI. Pharma Services revenue nearly doubled year-over-year, up 95%, with Pharma Test revenue surging 187%. The company also appointed Maria Ekdahl as CFO and expects the rights issue subscription period to open no later than 7 October 2026.
Tempus AI, Inc. Class A Common StockBiovica terminated its agreement with Tempus AI, indicating a loss of business for Tempus.
Shanghai Henlius Biotech Inc
